Qingsong Health expects H1 loss attributable to shareholders of RMB 40 million-RMB 70 million vs profit year earlier

• Qingsong Health forecast a loss attributable to shareholders of RMB 40 million to RMB 70 million for the six months ended June 30, 2026.
• That compares with a profit attributable to shareholders of RMB 86 million a year earlier.
• Loss excluding non-recurring items also seen at RMB 40 million to RMB 70 million versus RMB 51.2 million profit previously; non-recurring items expected insignificant.
• Higher R&D spending tied to medical training data for AI model development weighed on results.
• Insurance customer acquisition costs rose, while digital marketing revenue fell on weaker budgets from major clients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qingsong Health Corporation published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260717-12248854), on July 17, 2026, and is solely responsible for the information contained therein.